Cytochrome P450 - Physiological key factor against cholesterol accumulation and the atherosclerotic vascular process

Annals of Medicine

Volumn 39, Issue 5, 2007, Pages 359-370

  Luoma, Pauli V ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

ABC transporter; Apolipoprotein AI; CYP; Cytochrome P450; Gene activation; HDL; Induction; LXR; Oxysterol; PPAR

Indexed keywords

ABC TRANSPORTER; ADENOSINE A2 RECEPTOR AGONIST; ANTICONVULSIVE AGENT; APOLIPOPROTEIN; BEZAFIBRATE; COLECALCIFEROL RECEPTOR; COLESTYRAMINE; CONSTITUTIVE ANDROSTANE RECEPTOR; CYTOCHROME P450; FARNESOID X RECEPTOR; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GAMMA INTERFERON; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; KETOCONAZOLE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; MEVINOLIN; OXYSTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHENOBARBITAL; PIOGLITAZONE; PITAVASTATIN; PREGNANE X RECEPTOR; RETINOL DERIVATIVE; ROSIGLITAZONE; SIMVASTATIN; STEROID; THIAZIDE DIURETIC AGENT;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; GENE ACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; CHOLESTEROL, HDL; CYTOCHROME P-450 ENZYME SYSTEM; DNA-BINDING PROTEINS; ENDOTHELIUM, VASCULAR; HUMANS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 34547887264     PISSN: 07853890     EISSN: 16512219     Source Type: Journal    
DOI: 10.1080/07853890701379767     Document Type: Review

References (157)

1. Omura T, Sato R. The carbon-monoxide-binding pigment in liver microsomes. II. Solubilization, purification and properties. J Biol Chem. 1964;239:2379-85.
2. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet. 2002;360:1155-62.
3. Luoma PV, Sotaniemi EA, Pelkonen RO, Myllylä VV. Plasma high density lipoprotein cholesterol and hepatic cytochrome P-450 concentrations in epileptics undergoing anticonvulsant treatment. Scand J Clin Lab Invest. 1980;40:163-7.
4. Luoma PV, Sotaniemi EA, Pelkonen RO, Ehnholm C. Plasma high density lipoprotein and liver microsomal enzyme activity in man. In: Pilli-Sihvola AS, Laaksovirta TH, editors. The Medical Research Council 1977-1979. Helsinki: The Academy of Finland; 1980. p. 71.
5. Luoma PV, Sotaniemi EA, Pelkonen RO, Arranto A, Ehnholm C. Plasma high density lipoproteins and hepatic microsomal induction - relation to histological changes in the liver. Eur J Clin Pharmacol. 1982;23:275-82.
6. Luoma PV, Sotaniemi EA, Pelkonen RO. Inverse relation of serum LDL cholesterol and the LDL/HDL cholesterol ratio to liver microsomal induction in man. Res Commun Chem Pathol Pharmacol. 1983;42:173-6.
7. Luoma PV, Sotaniemi EA, Arranto AJ. Serum LDL cholesterol and LDL/HDL cholesterol ratio and liver microsomal induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest. 1983;43:671-5.
8. Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature. 1996;383:728-31.
9. Lehmann JM, Kliewer SA, Moore LB, Smith-Oliver TA, Oliver BB, Su JL, et al. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J Biol Chem. 1997;272:3137-40.
10. Björkhem I, Andersson O, Diczfalusy U, Sefastik B, Xiu R-J, Duan C, et al. Atherosclerosis and sterol 27-hydroxylase: Evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc Natl Acad Sci U S A. 1994;91:8592-6.
11. Reiss AB, Martin KO, Javitt NB, Martin DW, Grossi EA, Galloway AC. Sterol 27-hydroxylase: high levels of activity in vascular endothelium. J Lipid Res. 1994;35:1026-30.
12. Björkhem I, Diczfalusy U, Lütjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr Opin Lipidol. 1999;10:161-5.
13. Wang N, Silver DL, Costet P, Tall AR. Specific binding of apoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABCA1. J Biol Chem. 2000;275:33053-8.
14. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A. 2004;101:9774-9.
15. Klucken J, Büchler C, Orsó E, Kaminski WE, Porsch-Özcrmez M, Liebisch G, et al. ABCG1 (ABC8), the human homolog of the drosophila white gene, is regulator of macrophage cholesterol and phospholipid transport. Proc Natl Acad Sci U S A. 2000;97:817-22.
16. Luoma PV. Gene activation, apolipoprotein A-I/ high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol. 1997;81:57-64.
17. Luoma PV, Savolainen MJ, Sotaniemi EA, Pelkonen RO, Arranto AJ, Ehnholm C. Plasma high density lipoprotein and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction. Acta Med Scand. 1983;214:103-9.
18. Chao YU, Pickett CB, Yamin TT, Guo LS, Alberts A, Kroon PA. Phenobarbital induces rat liver apoliprotein A-I mRNA. Mol Pharmacol. 1985;27:394-8.
19. Malmendier CL, Delcroix C. Effect of alcohol intake on high and low density lipoprotein metabolism in healthy volunteers. Clinica Chimica Acta. 1985;152:281-8.
20. Malmendier C, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 1985;55:161-9.
21. Saku K, Gartside PS, Hynd BA, Kashyap ML. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest. 1985;75:1702-12.
22. Tam SP. Effects of gemfibrozil and ketoconazole on human apolipoprotein A-I and E levels in two hepatoma cell lines HepG2 and HepG3. Atherosclerosis. 1991;91:51-61.
23. Tam SP. Effect of ethanol on lipoprotein secretion in two human hepatoma cell lines HepG2 and HepG3. Alcohol Clin Exp Res. 1992;16:1021-8.
24. Rubin EM, Krauss MR, Spangler EA, Verstuyft JG, Clift MS. Inhibition of early atherogenesis in transgenic mice by human apoprotein A-I. Nature. 1991;353:265-7.
25. Duverger N, Kruth NH, Emmanuel F, Caillaud JM, Viglietta C, Castro G, et al. Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation. 1996;94:713-7.
26. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation. 1999;100:594-8.
27. Russell DW. Oxysterol biosynthetic enzymes. Biochim Biophys Acta. 2000;1529:126-35.
28. Tontonoz P, Mangelsdorf DJ. Liver X receptors signalling pathways in cardiovascular disease. Mol Endocrinol. 2003;17:985-93.
29. Ory DS. Nuclear receptor signalling in the control of cholesterol homeostasis: have the orphans found a home. Circ Res. 2004;95:660-70.
30. Russell DW. The enzymes, regulation and genetics of bile acid synthesis. Annu Rev Biochem. 2003;72:137-74.
31. Björkhem I, Diczfalusy U. Oxysterols-friends, foes or just fellow passengers. Arterioscler Thromb Vasc Biol. 2002;22:734-42.
32. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, et al. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol loaded cells. J Biol Chem. 2001;276:38378-87.
33. Escher G, Krozowski Z, Croft KD, Sviridov D. Expression of sterol 27-hydroxylase (CYP27A1) enhances cholesterol efflux. J Biol Chem. 2003;278:11015-9.
34. Norlin M, Andersson U, Björkhem I, Wikwall K. Oxysterol 7α-hydroxylase activity by cholesterol 7α-hydroxylase (CYP7A). J Biol Chem. 2000;275:34046-53.
35. Björkhem I, Meaney S. Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol. 2004;24:806-15.
36. Dietschy JM, Turley SD. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res. 2004;45:1375-97.
37. Lütjohann D, Breuer O, Ahlborg G, Nennesmo I, Sidén Å, Diczfalusy U, et al. Cholesterol homeostasis in human brain: Evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into circulation. Proc Natl Acad Sci U S A. 1996;93:9799-804.
38. Li-Hawkins J, Lund EG, Bronson AD, Russell DW. Expression cloning of an oxysterol 7α-hydroxylase selective for 24-hydroxycholesterol. J Biol Chem. 2000;275:16543-48.
39. Abildayeva K, Jansen PJ, Hirsch-Reinshagen V, Bloks WV, Bakker AHF, Ramaekers FCS, et al. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J Biol Chem. 2006;281:12799-808.
40. Pfrieger FW. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes. Bioessays. 2002;25:72-8.
41. Panzenboeck U, Balazs Z, Sovic A, Hrzenjak A, Levak-Frank S, Wintersperger A, et al. ABCA1 and scavenger receptor class B, type I, are modulators of reverse cholesterol transport at an in vitro blood-brain barrier constituted porcine brain capillary endothelial cells. J Biol Chem. 2002;277:42781-9.
42. Lütjohann D, Papassotiropoulos A, Björkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res. 2000;41:195-8.
43. Bodin K, Bretillon L, Aden Y, Bertilsson L, Broome U, Einarsson C, et al. Antiepileptic drugs increase plasma levels of 4β-hydroxycholesterol in humans. J Biol Chem. 2001;276:38685-9.
44. Gibbons GF. The role of cytochrome P450 in the regulation of cholesterol biosynthesis. Lipids. 2002;37:1163-70.
45. Ridgway ND, Dawson PA, Ho YK, Brown MS, Goldstein JL. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. J Cell Biol. 1992;116:307-19.
46. Olkkonen VM, Johansson M, Suchanek M, Yan D, Hynynen R, Ehnholm C, et al. The OSBP-related proteins (ORPS): global sterol sensors for co-ordination of cellular lipid metabolism, membrane trafficking and signalling processes. Biochem Soc Transact. 2006;34:389-91.
47. Raychaudhuri S, Im YJ, Hurley JH, Prinz WA. Nonvesicular sterol movement from plasma membrane to ER requires oxysterol-binding protein related proteins and phosphoinositides. J Cell Biol. 2006;173:107-19.
48. Chawla A, Boisvert W, Lee C-H, Laffitte BA, Barak Y, Joseph SB, et al. A PPARγ- LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell. 2001;7:161-71.
49. Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat Genet. 1999;22:347-51.
50. Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet. 1999;22:336-45.
51. Rust S, Rosier M, Funke H, Real J, Amoura Z, Piett JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat Genet. 1999;22:352-5.
52. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-31.
53. Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, et al. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc Natl Acad Sci U S A. 2002;99:11896-901.
54. Schuster GU, Parini P, Wang L, Alberti SA, Steffensen KR, Hansson GK, et al. Accumulation of foam cells in liver X receptor-deficient mice. Circulation. 2002;106:1147-53.
55. Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, et al. Increased ABCA1 activity protects against atherosclerosis. J Clin Invest. 2002;110:35-42.
56. Brewer HB Jr, Remaley AT, Neufeld EB, Basso F, Jouce C. Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler Thromb Vasc Biol. 2004;24:1755-60.
57. Timmins JM, Lee J-Y, Boydyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abc 1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest. 2005;115:1333-42.
58. Brunham LR, Kruit KJ, Iqbal J, Fievet C, Timmins JM, Pape T, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest. 2006;116:1052-62.
59. Repa JJ, Turley SD, Lobaccaro JA, Medina J, Li L, Lustig K, et al. Regulation of absorption of ABCA1-mediated efflux of cholesterol by RXR heterodimers. Science. 2000;289:1524-9.
60. Yu L, Li-Hawkins J, Hammer RE, Berge KE, Horton JD, Cohen JC, et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J Clin Invest. 2002;110:671-80.
61. Kruit JK, Plösch T, Havinga R, Boverhof R, Groot PEH, Groen AK, et al. Increased fecal neutral steroid loss upon liver-X-receptor activation is independent of biliary sterol secretion in mice. Gastroenterology. 2005;128:147-56.
62. Berge KE, Tian H, Graf GA, Yu L, Grishin NV, Schutz J, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290:1771-5.
63. Chinetti G, Lestavel S, Bocher V, Remaley AT, Neve B, Torra IP, et al. PPARα and PPARγ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med. 2001;7:53-8.
64. Li AC, Glass CK. PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis. J Lipid Res. 2004;45:2161-73.
65. Mak PA, Laffitte BA, Resrumaux C, Joseph SB, Curtiss LK, Mangelsdorf DJ, et al. Regulated expression of the apolipoproteinE/C-I/C-IV/C-CII gene cluster in murine and human macrophage. A critical role for nuclear liver X receptors α and β. J Biol Chem. 2002;277:31900-8.
66. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JM, et al. Protection against atherogenesis in mice mediated by human apolipoprotein AIV. Science. 1996;273:966-8.
67. Liang Y, Jiang X-C, Liu R, Liang G, Beyer TP, Gao H, et al. Liver X receptors (LXRs) regulate apolipoprotein AIV - implications of the antiatherosclerotic effect of LXR agonists. Mol Endocrinol. 2004;18:2000-10.
68. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JMA, Shimomura I, et al. Regulation of mouse sterol regulatory element-binding protein-1c (SREBP-1c) by oxysterol receptors LXRα and LXRβ. Genes Dev. 2000;14:2819-30.
69. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002;109:1125-31.
70. Malerod L, Juvet LK, Hanssen-Bauer A, Eskild W, Berg T. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun. 2002;299:916-23.
71. Ji Y, Jian B, Wang N, Sun Y, de la Llera Moya M, Phillips MC, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem. 1997;272:20982-5.
72. Eloranta JJ, Kullak-Ublick GA. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys. 2005;433:397-412.
73. Claudel T, Staels B, Kuipers F. The farnesoid X receptor - a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol. 2005;25:2020-31.
74. Bodin K, Lindbom U, Diczfalusy U. Novel pathways of bile acid metabolism involving CYP3A4. Biochim Biophys Acta. 2005;1687:84-93.
75. Goodwin B, Moore JT. CAR: detailing new models. Trends Pharmacol Sci. 2004;25:437-41.
76. Prueksaritanont T, Richards KM, Qui Y, Strong-Basalyga K, Miller A, Li C, et al. Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes. Pharmaceut Res. 2005;22:71-8.
77. Amacher D, Beck D, Schomaker SJ, Kenny CV. Hepatic microsomal enzyme induction, β-oxidation, and cell proliferation following administration of clofibrate, gemfibrozil or bezafibrate in the CD rat. Toxicol Appl Pharmacol. 1997;142:143-50.
78. Kocarek T, Dahn MS, Cai H, Strom SC, Mercer-Haines NA. Regulation of CYP2B6 and CYP3A expression by hydroxymethylglutaryl coenzyme A inhibitors in primary cultured human hepatocytes. Drug Metab Dispos. 2002;30:1400-5.
79. Kobayashi K, Yamanaka Y, Iwazaki N, Nakajo I, Hosokawa M, Negishi M, et al. Identification of HMG-CoA reductase inhibitors as activators for human, mouse and rat constitutive androstane receptor. Drug Metab Dispos. 2005;33:924-9.
80. Fan P, Zhang B, Kuroki S, Saku K. Pitavastatin, a potent hydroxymethylglutaryl coenzyme A reductase inhibitor, increases cholesterol 7α-hydroxylase gene expression in HepG2 cells. Circ J. 2004;68:1061-6.
81. Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, et al. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab Dispos. 2003;31:439-46.
82. Lieber CS. To drink (moderately) or not to drink? N Engl J Med. 1984;310:846-8.
83. Luoma PV Sotaniemi EA, Pelkonen RO, Ehnholm C. High-density lipoproteins and hepatic microsomal enzyme induction in alcohol consumers. Res Commun Chem Pathol Pharmacol. 1982;37:91-6.
84. Reiss AB, Rahman M, Chan ES, Montesinos C, Awadallah NW, Cronstein BN. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leucoc Biol. 2004;76:727-34.
85. Langmann T, Liebisch G, Moehle C, Schifferer R, Dayoab R, Heiduczek S, et al. Gene expression profiling identifies retinoids as potent inducers of macrophage lipid efflux. Biochim Biophys Acta. 2005;1740:155-61.
86. Staels B, Dallongville D, Auwerx J, Schhoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-93.
87. Arakawa R, Tamehiro N, Nishimaki-Mogami T, Ueda K, Yokoyama S. Fenofibric acid, an active form of fenofibrate increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter AI gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005;25:1193-7.
88. Knight BL, Patel DD, Humphreys SM, Wiggins D, Gibbons GF. Inhibition of cholesterol absorption associated with a PPARα-dependent increase in ABC binding cassette transporter A1 in mice. J Lipid Res. 2003;44:2049-58.
89. Guan J-Z, Tamasava N, Murakami H, Matsui J, Yamato K, Suda T. Clofibrate, a peroxisome-proliferator, enhances reverse cholesterol transport through cytochrome P450 activation and oxysterol generation. Tohoku J Exp Med. 2003;201:251-9.
90. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, et al. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl- CoA reductase inhibition. J Biol Chem. 2005;280:22212-21.
91. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al. Y. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun. 2004;324:835-9.
92. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARα and induces HDL apoA-I. J Clin Invest. 2001;107:1423-32.
93. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. Human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest. 1998;102:1016-23.
94. Fajas L, Schoonjans K, Gelman L, Kim JB, Najib J, Martin G, et al. Regulation of peroxisome proliferator-activated receptor gamma expression by adipocyte differentation and determination factor1/sterol regulatory element binding protein 1: implications for adipocyte differentiation and metabolism. Mol Cell Biol. 1999;19:5495-503.
95. Glueck CJ. Nonpharmacologic and pharmacologic alteration of high-density lipoprotein cholesterol: therapeutic approaches to prevention of atherosclerosis. Am Heart J. 1985;110:1107-15.
96. Shepherd J. The effect of cholestyramine on high density lipoprotein metabolism. Atherosclerosis. 1979;33:433-44.
97. Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-deoxy-Δ 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell. 1995;83:803-12.
98. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor PPARγ. J Biol Chem. 1995;270:12953-6.
99. Myers CD, Kashyap ML. Pharmacological augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol. 2005;20:307-12.
100. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, et al. Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1 and apo E in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22:2607-19.
101. Chinetti G, Gbaguidi FG, Griglio S, Mallat Z, Antonucci M, Poulain P, et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation. 2000;101:2411-7.
102. Szanto A, Benko S, Szatmari I, Balint LB, Furtos I, Rhl R, et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signalling in macrophages. Mol Cell Biol. 2004;24:8154-66.
103. Quinn CM, Jessup W, Wong J, Kritharides L, Brown AJ. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands. Biochem J. 2005;385:823-30.
104. Luo G, Cunningham M, Kim S, Burn T, Lin J, Sinz M, et al. 3A4 induction by drugs: correlation between a pregnane x receptor receptor gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Disp. 2002;30:795-802.
105. Moore LB, Parks DJ, Jonest SA, Bledsoe RK, Consler TG, Stimmel JB, et al. Orphan nuclear receptors constitutive androstane receptor and Pregnane receptor share xenobiotic and steroid ligands. J Biol Chem. 2000;275:15122-7.
106. Makishima M, Lu TT, Xie W, Whitfield GK, Domoto H, Evans RM, et al. Vitamin D receptor as an intestinal bile acid sensor. Science. 2002;296:1313-6.
107. Beulens JW, Sierksma A, van Tol A, Fournier N, van Gent T, Paul J-L, et al. Moderate alcohol consumption increases cholesterol efflux mediated by ABCA1. J Lipid Res. 2004;45:1716-23.
108. Costet P, Lalanne F, Gerbod-Gionnone M, Molina JR, Fu X, Lund EG, et al. Retinoid acid receptor-mediated induction of ABCA1 in macrophages. Mol Cell Biol. 2003;23:7756-66.
109. Astrup P, Kjeldsen K, Wanstrup J. Effects of carbon monoxide exposure on the arterial walls. Ann NY Acad Sci. 1970;174:294-300.
110. Haustein KO, Krause J, Haustein H, Rasmussen T, Cort N. Comparison of the effects of combined nicotine replacement therapy vs. cigarette smoking in males. Nicotine Tob Res. 2003;5:195-203.
111. Moffatt RJ, Stamford BA, Biggerstaff KD. Influence of worksite tobacco smoke on serum lipoprotein profiles of female nonsmokers. Metabolism. 1995;44:1536-9.
112. Hedblad B, Ögren M, Engström G, Wollmer P, Janzon L. Heterogeneity of cardiovascular risk among smokers is related to degree of carbon monoxide exposure. Atherosclerosis. 2005;179:177-83.
113. Reiss AB, Patel CA, Rahman MM, Chan ESL, Hasneen K, Montesinos MM, et al. Interferon-γ impedes reverse cholesterol transport and promotes foam cell transformation in TPH-1 human monocytes/macrophages. Med Sci Monit. 2004;10:BR420-5.
114. Williams JF. Cytochrome isoforms. Regulation during infection, inflammation and by cytokines. J Fla Med Assoc. 1991;78:517-9.
115. Panousis VG, Zuckerman SH. Interferon-γ induces down-regulation of Tangier disease gene (ATP-binding cassette transporter 1) in macrophage derived foam cells. Arterioscler Thromb Vasc Biol. 2000;20:1565-71.
116. von Bahr S, Movin T, Papadogiannakis N, Pikuleva I, Rönnow P, Diczfalusy U, et al. Mechanism of accumulation of cholesterol and cholestanol in tendons and the role of sterol 27-hydroxylase (CYP27A1). Arterioscler Thromb Vasc Biol. 2002;22:1129-35.
117. Pullinger CR, Eng C, Salen G, Shefer S, Barra AK, Erickson SK, et al. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110:109-17.
118. Frick MH, Syvänne M, Nieminen MS, Kauma H, Majahalme S, Virtanen V, et al. Prevention of the angiographic progression of coronary vein-graft atherosclerosis by gemfibrozil after coronary by-pass surgery in men with low levels of HDL cholesterol. Circulation. 1997;96:2137-43.
119. Ericsson CG, de Faire U, Grip L, Svane B, Hamsten A, Nilsson J. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet. 1996;347:849-53.
120. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet. 2001;357:905-10.
121. Effect of simvastatin on coronary atheroma. The Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-8.
122. Blankenhorn DH, Azen SP, Kramsch DM, Mack WJ, Cashin-Hemphill L, Hodis HN, et al., and the MARS Research Group. Coronary angiographic changes with lovastatin therapy; The Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-76.
123. Watts GF, Lewis B, Brunt JNH, Lewis Es, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid lowering diet, or diet plus cholestyramine. In St Thomas Atherosclerosis Regression Study (STARS). Lancet. 1992;339:563-9.
124. Langenfeld MR, Forst T, Hohberg C, Kann P, Lubben G, Konrad T, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomized study. Circulation. 2005;111:2525-31.
125. Myasnikov AL. Influence of some factors on development of experimental cholesterol atherosclerosis. Circulation. 1958;17:99-113.
126. Salvador RA, Atkins C, Haber S, Kozma C, Conney AH. Effect of phenobarbital and chlorcyclizine on the development of atheromatosis in the cholesterol-fed rabbit. Biochem Pharmacol. 1970;19:1975-81.
127. Kiehl S, Willeit J, Rungger G, Egger G, Oberhollenzer F, Bonora E, et al. Alcohol consumption and atherosclerosis: What is the relation. Prospective results from the Bruneck study. Stroke. 1998;29:900-7.
128. Femia R, Natali A, L'Abbate A, Ferrannini E. Coronary atherosclerosis and alcohol consumption. Angiographic and mortality data. Arterioscler Thromb Vasc Biol. 2006;26:1607-12.
129. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. New Engl J Med. 1987;317:1237-45.
130. Tenkanen L, Mänttäri M, Kovanen PT, Virkkunen H, Manninen V. Gemfibrozil in the treatment of dyslipidemia. An 18-year follow-up of the Helsinki Heart Study. Arch Intern Med. 2006;166:743-8.
131. Keech A, Simes RJ, Barter J, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9759 people with type 2 diabetes mellitus (the FIELD Study): randomised controlled trial. Lancet. 2005;366:1849-61.
132. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-9.
133. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
134. Cheung BMY, Lauder IJ, Lau C-P, Kumana C. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57:640-51.
135. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al., Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267-78.
136. The Lipid Research Clinics Coronary Primary Prevention Trial: results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984;251:351-64.
137. Dormandy JA, Charbonnel B, Eckland DAJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the Proactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89.
138. Poikolainen K. Alcohol and mortality: a review. J Clin Epidemiol. 1995;48:455-65.
139. Luoma PV, Savolainen MJ, Sotaniemi EA, Arranto AJ, Pelkonen RO. Plasma HDL cholesterol and blood glucose in non-insulin-dependent diabetics related to liver lipids and microsomal enzyme activity. Acta Med Scand. 1985;217:473-9.
140. Luoma PV, Rautio A, Stengård J, Sotaniemi EA, Marniemi J. High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects. Eur J Clin Pharmacol. 1990;38:625-7.
141. Tokola O, Pelkonen O, Karki NT, Luoma P. Hepatic drug-oxidizing enzyme systems and urinary D-glucaric acid excretion in patients with congestive heart failure. Br J Clin Pharmacol. 1975;2:429-36.
142. Luoma PV, Myllylä VV, Hokkanen E. Relationship between plasma high-density lipoprotein cholesterol and anticonvulsant levels in epileptics. J Cardiovasc Pharmacol. 1982;4:1024-7.
143. LaPorte R, Valvo-Gerard L, Kuller L, Wanju R, Bates M, Cresanta J, et al. The relationship between alcohol consumption, liver enzymes and high-density lipoprotein cholesterol. Circulation. 1981;64 suppl III: 67-72.
144. Steyn K, Fourie J, Benade AJ, Roussow JE, Langenhoven ML, Joubert G, et al. Factors associated with high density lipoprotein cholesterol in a population with high high density lipoprotein cholesterol levels. Arteriosclerosis. 1989;9:390-7.
145. Dixon RM, Borden EC, Keim NL, Anderson S, Spennetta TL, Tormey DC, et al. Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced recombinant DNA-derived leucocyte interferon. Metabolism. 1984;33:400-4.
146. Andrade RJ, Escolar JL, Valdivielso P, Gonzelez-Santos P. Apolipoprotein distribution in plasma HDL subfractions in alcohol consumers. Drug Alcohol Depend. 1990;26:161-8.
147. Robertson RG, Krause BR, Welty DF, Wolfgang GHI, Grazian MJ, Pilcher GD, et al. Hepatic microsomal induction profile of carbamic acid [[2,6-bis(1-methylethyl) phenoxy] sulfonyl]-2,6-bis(1-methylethyl) phenyl ester, monosodium salt (PD138142-15), a novel lipid regulating agent. Biochem Pharmacol. 1995;49:799-808.
148. Evans RM. The nuclear receptor superfamily: a rosette stone for physiology. Mol Endocrinol. 2005;19:1429-38.
149. Luoma PV, Sotaniemi EA, Ehnholm C. Low high-density lipoprotein and reduced antipyrine metabolism in members of a family with polycystic liver disease. Scand J Gastroenterol. 1980;15:869-73.
150. Luoma PV, Sotaniemi EA, Pelkonen RO, Pirttiaho HI. Serum low density and high density lipoprotein cholesterol, and liver size in subjects on drugs inducing hepatic microsomal enzymes. Eur J Clin Pharmacol. 1985;28:615-8.
151. Bretillon L, Lütjohann D, Ståhle L, Widhe T, Bindl L, Eggertsen G, et al. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J Lipid Res. 2000;41:840-5.
152. Lehrke M, Lebherz C, Millington SC, Guan HP, Millar J, Rader DJ, et al. Diet-dependent cardiovascular lipid metabolism controlled by hepatic LXRα. Cell Metab. 2005;1:297-308.
153. Joseph SB, Mckilligan E, Pei L, Watson MA, Collins AR, Laffitte BA, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci U S A. 2002;99:7604-9.
154. Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, et al. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 2003;536:6-11.
155. Kovanen PT, Pentikäinen MO. Pharmacological evidence for a role of liver X receptors in atheroprotection. FEBS Lett. 2003;536:3-5.
156. Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, et al. Macrophage liver X receptor is required for anti-atherogenic activity of LXR agonists. Arterioscler Thromb Vasc Biol. 2005;25:135-42.
157. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MR, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90-7.